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Introduction
Prevalence of cervical cancer
Cervical cancer is the third-most common cancer in the world 
and the second-most fatal in women, causing about 274,000 
deaths annually (Vici, 2014; de Noronha, 2013). Cervical cancer 
is a resilient cancer that is hard to eliminate. Screening programs 
are beneficial, even in young to middle-adult ages, when it leads 
to early detection and treatment, increasing chances of surviv-
al (de Noronha, 2013). Possible but unpleasant and not always 
successful treatments are monotherapy, radiation, chemotherapy, 
and drugs like Benacizumab (Vici, 2014). Researchers are also con-
cerned with quality of life, since the pelvic floor is affected after 
cancer has developed (de Noronha, 2013).  For these reasons, 
researchers decided to focus on the preventive aspect so fewer 
treatment options will be necessary. An individual can check for 
cervical cancer with a Pananicola test which detects precancer-
ous lesions that may eventually develop into cancer. Because of 
the increase of Pananicola testing recommended and performed, 
more people are aware of their cervical wellbeing (Markowitz et 
al., 2007). Many researchers noted that when they studied the 
pathogenesis of cervical cancer, 99% of cases and over 90% of 
squamous intra-epithelial lesions that appear before the cancer 
fully appears are actually caused by a virus, Human Papillomavirus 
(HPV) (Monie et al., 2008).  In fact, the biggest widespread sexually 
transmitted infection (STI) in the world is HPV; About 79 million 
people in the US currently are infected with HPV and about 14 
million people become infected each year (Markowitz et al., 2007). 
The cases increase with age until the mid-thirties age group, 
where the number of cases of HPV begins to decrease. HPV can 
cure itself, as it actually does in about 90% of cases. However, if 
an individual’s cervix does not heal, then she becomes at high risk 
for developing cervical cancer (Basu et al., 2013). Besides cervical 
cancer, HPV can also cause vaginal and vulvar cancer in women, 
penile cancer in men, and some oropharyngeal cancers and genital 
warts in both genders. Every year, about 26,200 new cancers are 
linked to HPV, and two-thirds of them affect women (Markowitz 
et al., 2007).
Pathogenesis of HPV
Of the 200 HPV genotypes, the majority of them can cause in-
fections that may result in “benign or self-limited tumors (warts) 
in the skin or in the genitals.” Those genotypes of HPV that do 
form warts are the oncogenic category of HPV (Wang & Roden, 
2013). There are about 13 high-risk HPV strains and another seven 
probable high-risk strains. The most common HPV strains world-
wide are HPV 16, 18, 31, 52 and 58 (Tachezy et al., 2013). The HPV 
virus can lead to cervical, vaginal, anal, pelvis, vulvar and oropha-
ryngeal cancers (Wang & Roden, 2013). The two most common 
HPV strains that are related to cervical cancer are HPV 16 (50% 
of all cases) and HPV 18 (20% of all cases). However, in anatomic 
locations other than the cervix that can be infected by HPV, such 
as the head and neck centers, HPV 16 is the cause of cancer 90% 
of the time (Monie et al., 2008). During intercourse, the epithelial 
cells of the cervix and vagina might acquire some abrasions, which 
raise the possibility of undifferentiated basal cells being exposed to 
a strain of HPV. If HPV is present, the cells might differentiate with 
the viral genome and begin to replicate (Wang & Roden, 2013).
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 HPV’s genome “encodes two classes of genes – early and late. The 
early genes control replication (E1, E2), transcription (E2), reorga-
nization (E4), and transformation (E5, E6, E7). The late proteins are 
structural components of the viral capsid.” However, the expres-
sion is controlled by the differentiation of the host - now infected 
- cell.  When development occurs, the HPV genome mixes into 
the host’s genome, causing E2, which is the main regulator of the 
virus’s genes, and L1 and L2 to be suppressed (Monie et al., 2008). 
That allows E6 and E7 to overregulate. E7 would lead the cell into 
the S-phase of uncontrollable replication and the cell cycle will 
be disrupted. Eventually a thickened epithelial lesion will form. Its 
cells will flow from the epithelium and a virus will spread.  HPV 
will then evolve into an HPV-related neoplasia and develop into 
warts or cancer if the immune system fails to protect the body 
(Basu et al., 2013).  
Genital warts are the largest cause of sexually transmitted infec-
tion in the Western world. Their treatment is excruciating and 
also not permanent, as the warts commonly recur. Besides the 
high costs of treatments for genital warts, the recurrence is also 
nerve-wracking and frustrating to a patient’s mental state. Genital 
warts generally come about from HPV 6 and 11 – two low risk 
HPV strains – but more research is needed to test for the pres-
ence of other strains, like the high risk HPV 16 and 18 (Szarewski 
et al., 2013).
Development of a vaccine
Because it takes years for an HPV infection to become a cancer, it 
is probably going to take years before researchers will be able to 
see the full results of the vaccines (Markowitz et al., 2007).  Two 
vaccines over the past decade were created to prevent the “grave 
outcomes of a long-lasting HPV infection and HPV-related ano-
genital maliganancies, high grade cervical intraephithelial neoplasia 
(CIN), VIN, VaIN, and AIN” (Wang & Roden, 2013).  The develop-
ment of vaginal, vulvar, and anal cancer is not yet fully understood. 
Unlike cervical cancer, there is no routine screening developed yet 
for vaginal and vulvar cancer. Vaginal and vulvar are not common 
cancers; 1,070 and 3,507 cases were reported in the US, respec-
tively (Markowitz et al., 2007).
The vaccines to prevent HPV are created by the use of virus-like 
particles (VLP) as the antigens needed to combat in the vaccines 
which come from the L1 surface protein of the precise types of 
HPV used in that specific vaccine (Basu et al., 2013). These VLPs 
are assisted by monoclonal antibodies (mAbs) for correctly fold-
ing into epitopes, virus typing and activating the proper immune 
response (Vidyasagar et al., 2014). The vaccine is considered dead 
as the VLPs are non-pathogenic and cannot cause other cells to 
become infected. Most importantly, the VLPs lack the viral ge-
nome. When a person is injected with the vaccine, the body re-
sponds and develops a high concentration of serum immunoglobin 
G antibody against those specific HPV types. Those antibodies are 
released in the cervico-vaginal secretion, and are also released 
when the epithelium acquires micro-abrasions. In this case, the 
antibodies will fight off any hint of infection before the virus has 
a chance to penetrate the basal keratinocytes in the vagina and 
cervix and infect them with HPV (Basu et al., 2013). 
CIN usually precedes HPV and can be graded from CIN 1 through 
CIN 3, with CIN 3 being the most severe. CIN 2 and CIN 3 are 
dangerous and are believed to be “pre-malignant lesions, as over 
time CIN 3 has a 30 to 50 percent chance of becoming cancer-
ous.” Screening for cancerous cells in the cervix is generally ob-
served during the CIN 2 and CIN 3 stages and with treatment, the 
cells may be stopped from developing into a cancer. Vaccines can 
stop CIN 2 and CIN 3 from developing altogether by preventing 
the infection of the common HPVs which eliminates the chance 
of cancer growth of those specific strains. The goal of the HPV 
vaccine is to prevent at least CIN 2 (Basu et al., 2013).
Because the vaccine is made from VLPs, it is considered a dead 
vaccine, since no live HPV ever enters the body in order to pro-
duce antibodies. Cervarix and Garsdasil are based on insect and 
yeast cells, yielding a high cost for the vaccinations compared to 
those that are based on Escherichia Coli. The vaccines are actually 
from virus-like particles (VLPs) that can be created by expressing 
the recombinant L1 from mammals, insects, yeast, and bacteria. 
VLPs are similar to the virions in structure and immunology. 
Studies have shown that these VLPs can cause high concentrations 
of serum antibodies (IgG) and can also protect against papillo-
mavirus in the outside body layers.  When trials began for the 
L1 vaccines, it was noted that they caused a 40 times increase in 
concentration of antibodies in the serum in the average person 
(Basu et al., 2013). 
Vaccine coverage
Both vaccines prevent the two most common HPV strains, HPV 16 
and HPV 18. Gardasil is a quadrivalent vaccine, preventing against 
four different types of HPV – HPV 6, 11, 16, and 18. However, HPV 
6 and HPV 11 are low-risk HPV strains which are the main causes 
of “genital warts and laryngeal papillomas.” This creates Gardasil’s 
ability to prevent cervical cancer and genital warts. Gardasil is 
prepared using VLPs from recombinant yeast (Basu et al., 2013). 
Cervarix is bivalent, meaning it can only inhibit two types of HPV, 
which are the most potent types, HPV 16 and HPV 18. The vac-
cinated population remain at risk of developing cervical cancer 
that is caused by other strains of HPV, yet the chances of this 
happening are much lower. Nevertheless, recent studies show that 
Cervarix also protects against HPV 31 and HPV 45 because of 
its close genotype, making Cervarix’s protection rate of all HPVs 
close to 80 percent (Basu et al., 2013). It has also been proven that 
these vaccinations “inhibit HPV-associated neoplasia in the vagina, 
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vulvar, anus, in addition to HPV 16 detection in oral rinses” (Wang 
& Roden, 2013). Cervarix is also different from Gardasil in that it 
is made from insect cells, allowing those with yeast allergies to be 
vaccinated.
Another important difference between the two vaccines is the ad-
juvant used. Because synthetic antigens and pure recombinant do 
not yield sufficient antigens in the body to build a strong response 
of antibodies, a new idea of adjuvants, something added to a vac-
cine to promote the antibodies’ response to the antigen, began 
to spread in the immunological world. Merck uses an alum-based 
adjuvant for Gardasil. Alum-based adjuvant is actually the most ac-
cepted adjuvant worldwide because of its effective Th2 response 
and its side effects – local and systemic effects like myofascitis 
and eosinophilia are atypical and infrequent (Petrovsky & Aguilar, 
2004). Vaccines also have an adjuvant to help expose the antigen 
to the body for long periods of time so that the body can build a 
complete adaptive response for future use. The adjuvant used for 
Cervarix is ASO4, but not much is known its effects (Monie et al., 
2008).
Who should be vaccinated
Cervarix and Gardasil are the first vaccine pair in history that 
focus on the same objective the same way just made by different 
companies. However, they are not interchangeable. Besides that 
Gardasil is a quadrivalent vaccine and prevents more than cervical 
cancer, it can also be used on the male population, while Cervarix 
cannot. 
  Gardasil is approved for males and females ages nine through 
twenty-six. However, the recommended age of HPV vaccination is 
ages 10-25.  Based on studies performed on various ages, the pre-
teens (10-15 years old) contained a higher “anti-HPV neutralizing 
antibodies response” than the group of 16- to 23-year-old females. 
Also, for maximum vaccine effect, it should be administered before 
the person engages in sexual activity (Basu et al., 2013). Pregnant 
women should not be vaccinated (Gardasil.com, 2013; Cervarix.
com, 2013). It is recommended that boys also receive the vaccine 
during their teenage years. The vaccine seems to be less effective 
for boys than for girls. The fact that boys may depend on the girls 
being vaccinated also downplays the urgency of all boys getting 
vaccinated. Gardasil recommends boys and men to be vaccinated 
from ages nine through twenty-six to prevent anal cancer caused 
by HPV 16 and 18, genital warts caused by HPV 6 and 11, and anal 
intraepithelial grades 1, 2, and 3. Cervarix has not yet been ap-
proved in the US for males as more studies are needed to decide 
whether it is potent.
Administration
Gardasil is an intramuscular injection; is administered three times 
in either the deltoid muscle or the upper thigh region. The second 
dose is given two months after the first, and the third dose is 
administered four months later. Clinical studies have shown that 
three doses administered within one year create maximum effica-
cy for the patient (Gardasil.com, 2013). 
Cervarix’s instruction label has similar directives as Gardasil’s. 
Cervarix is for females ranging from ages 9-25, and it is an 
Table 1-
The similarities and differences of the two available vaccines for HPV prevention:  Some countries only have one vaccine available, like Canada, and others have 
both vaccines available, like the United States. (Source: Dawar et al., 2007)
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intramuscular injection –preferably in the deltoid – that should 
be administered three times: the second a month after the first 
injection and the third six months after the original injection. The 
common side effects are swelling and redness in the area of where 
the vaccine was administered, headaches, fatigue, syncope, myalgia, 
and gastrointestinal symptoms.  Because of the dangers of syn-
cope, as with a Gardasil injection, it is necessary for all patients 
to wait fifteen minutes in the medical office before leaving for 
observation (Cervarix.com 2013).
One major concern about Cervarix and Gardasil is their limita-
tions in preventing cervical cancer. They do not guarantee a 100% 
success rate against cervical cancer, as Cervarix only fully protects 
against two strains of HPV and partially cross-protects against 
another two. HPV 33, HPV 52 and HPV 58 are other highly po-
tent strains that are not protected and may cause cervical cancer. 
Therefore, a broader vaccine is still needed to protect fully against 
around 90 percent of all cancer-causing strains. Some researchers 
believe that the future plans of cervical cancer vaccines should 
implement L2 as the antigen to use to cultivate a broad spectrum 
of antibodies (Basu et al., 2013).
Another major concern which Basu, Banerjee, Singh et al., raise 
is the unknown knowledge of how long the vaccine is viable and 
active. Because these vaccines are new, studies regarding their ef-
ficacy are not abundant. Perhaps a booster is needed after a few 
years. Banerjee and his fellow researchers state in their report 
that studies show that immunity seems to last for about 5.5 years. 
However, that is not long enough, as pediatricians believe that pre-
teens are the ideal age for the vaccines and as aforementioned, the 
manufacturers’ recommended age for receiving these vaccines is 
between ages 10-25. Therefore, if a child is 11 when she receives 
the vaccine, she will be 16.5 when the vaccine loses its effect, 
while she is still a growing and developing teenager.  In addition, 
not enough years have passed to fully observe the long-term ef-
fect this vaccine has on people.
Basu says that around the age of thirty people begin to develop 
their own antibodies against the virus. However, there is a 12.5-
year gap between the time when the vaccine diminished and when 
an individual became naturally immune to it. On the other hand, 
more research is needed on the exact length of protection against 
HPV in order to conclude whether a longer length of vaccine 
protection is needed, a booster should be administered, or the 
current vaccines Cervarix and Gardasil are sufficient (Basu et al., 
2013).
Prevention, not treatment
The vaccine does not mitigate or affect pre-existing HPV in any 
way.  The basal epithelial cells and cervical cancer cells do not 
seem to exhibit a considerable amount of their capsid antigen, L1 
or L2. If a vaccine targets the L1 or L2, these cells would remain 
untouched. The true need is to rid all HPV from the world; how-
ever, there are too many people who are already infected and are 
infecting those who are unprotected. (Basu et al., 2013). Therefore, 
it is crucial to remember that for an individual already infected 
by HPV, the best course of action is to consider treatment with 
medications, as the vaccine would be ineffective at this point. New 
research is being done to perhaps target the E6 and E7 proteins 
to help those who are already infected and therefore cannot use 
the vaccine as a solution. In the meantime, infected patients should 
resort to chemotherapy, radiation, surgery, and antibody therapy 
as possible treatments (Han & Sin, 2013).
Side effects of Gardasil
According to Gardasil’s website, the vaccine has a few minor side 
effects: redness or swelling around the injection site, headaches, 
dizziness, nausea, fainting and fever. In 2009, due to an increase 
of fainting and syncope, the FDA took initiative and ordered the 
manufacturer of Gardasil, Merck, to add on to the instruction label 
that it is mandatory for every patient to sit in the office for 15 
minutes upon injection.  The FDA says that by having the patient lie 
or sit in one position for fifteen minutes, the medical supervisor 
can monitor for the initial symptoms that generally develop into 
syncope, such as paleness, dizziness, sweating, changes in vision 
and ringing in the ears (Sullivan, 2009).  According to Gardasil, the 
most common side effect is headaches. However, Sullivan states 
that syncope following injection should not be taken lightly, as 
about 40 percent of syncope cases as a side effect develop into a 
tonic-clonic seizure-like activity which necessitates hospitalization. 
If a syncope or seizure-like activity occurs, the health professional 
should have the patient lie down to allow blood to continue circu-
lating throughout the body. (Merck points out that fainting is not 
a side effect only to Gardasil, as it is also common after donating 
blood, receiving other injections, and is a typical response to pain.) 
(Sullivan, 2009)
From January 2005 until July 2007, 70 cases of syncope resulting 
from a Gardasil injection were reported. According to Sullivan 
in her Pediatricnews.com article, about five percent of the cases 
were considered serious, 38 cases occurred on the vaccination 
day, and 37 cases required hospitalization. As of May 2009, out 
of 24 million vaccinations, 13,758 VAERS reports were filed. 93 
percent of those reports were considered not serious, including 
symptoms such as fainting, swelling, fever, headaches, and nausea. 
However, seven percent of those events were considered serious 
(Sullivan, 2009).
Immune response difference
Throughout studies, it has become evident that Cervarix produces 
a larger antibody response than Gardasil. In one study performed 
by GSK testing the two vaccines, “geometric mean titers of serum 
neutralizing antibodies ranged from 2.3- to 4.8-fold higher for 
HPV-16 and 6.8- to 9.1-fold higher for HPV-18 after vaccination 
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with Cervarix, compared with Gardasil, across all ages” (Einstein 
et al., 2009). One major possibility which researchers focus on 
is the ASO4 adjuvant, as both vaccines use VLPs. Although it is 
unknown for how long each vaccine is viable, one study claims 
Cervarix lasts up to 6.4 years. However, both manufacturers be-
lieve that they will know when the vaccine becomes irrelevant 
before the people who were already vaccinated will lose their 
protection.
How do most healthcare professionals decide which of the two to 
give? It will usually depend on the cost. However, patients should 
be notified of the benefits and differences of the two vaccines be-
cause they are not interchangeable in their protection (Pichichero, 
2009).
HPV infections cannot be treated; only their lesions may undergo 
treatment. Treatment options for the precursors of genital wart, 
vaginal and vulvar lesions have different options of removing the 
lesion and therapy. 
Methods
The information in this research paper was obtained from many 
journals, studies and research papers from the national website 
of Pubmed and Touro College’s Online Library and Database. This 
paper’s purpose is to educate the reader about what HPV is, how 
it develops into a cancer, why a vaccine is necessary, and how 
the vaccine is assembled. In addition, this paper will point out the 
different treatments for HPV, cancer, and genital warts and how a 
vaccine will make an imprint on the world. Using the manufactur-
ers’ (Merck’s and GSK’s) websites the reader will develop a vast 
knowledge of every aspect of the vaccines, ranging from what they 
cover to who should be vaccinated. Also, studies conducted on 
the vaccines will be examined to find any inaccuracy that exists 
which might lead those who are not knowledgeable in this area 
to be misinformed, and to help the reader develop his/her own 
opinion on the matter. Lastly, the effects of the vaccine on the 
world will be analyzed to see what the future has in store for its 
future of HPV and all that it may cause. 
Discussion
A study was done in 2003 by the Future II study group of the New 
England Journal of Medicine on a newly developed quadrivalent 
vaccine, which eventually became Gardasil, on the recommenda-
tions of the World Health Organization (WHO) and the FDA. The 
goal of the study was to determine the efficiency of the vaccine 
against HPV 6, 11, 16, and 18 and lesions. The study consisted of 
12,167 non-pregnant women from 131 different countries who 
had normal Papanicolaou smear results and had not had more 
than four partners in their lifetimes. After the subjects were vac-
cinated, they were evaluated by gynecologists for the average of 
the three years for which they were observed. At the conclusion 
of the study, it appeared that the vaccine is 98% effective in the 
population that was never exposed to HPV 16 and 18. However, 
the vaccine was only 44% effective in the pre-exposed popula-
tion to HPV and cervical lesions. In other words, 42 subjects of 
this study were infected within the first three years. Once again, 
the idea that researchers do not know what to expect past the 
years of research is alarming. Also, the pharmaceutical company 
Merck, which is currently the supplier of Gardasil, sponsored this 
study. There might be a risk of bias because of the financial backer 
(Future II Study Group, 2007).
Prophylactic vaccines that fight against HPV 16 and 18 have a 
high success rate against CIN 2 and 3 and some external genital 
lesions. However, because much is needed to persuade the pop-
ulation of the success of the vaccine to prevent CIN, a study was 
done to create a baseline before the creation and availability of 
HPV vaccines to the world. 
The subjects of this study were from population-based reg-
istries from Denmark, Iceland, Norway and Sweden who were 
“diagnosed with incident cervical vulvar and vaginal cancer and 
pre-invasive neoplasia  from January 1, 2004 until December 31, 
2006, with only the primary tumors allowed to be included yield-
ing to over 100,000 subjects in the number.” According to the 
data collected in all countries, the age range of 20 through 29 
years old experienced an immense increase of cases and a peak 
in the thirties age range for cervical cancer, yielding about 10 per-
cent of the cases. However, cervical pre-invasive neoplasia was 
most commonly found in people in their twenties in all four coun-
tries. Nevertheless, vulvar and vaginal cancer peak past the age 
of 40 and peak in women over 70. These researchers were able 
to mathematically predict the impact of vaccination by including 
the fact that only 30% of CIN3 would develop into cancer if not 
treated. Besides the fact that overtreatment of CIN3 is costly, it 
is dangerous for those in their reproductive years, as it increases 
the risk of preterm births. Therefore, it is in the best interests of 
all involved to prevent neoplasia in women. The researchers state 
that if the vaccine is really close to 100% efficacy, based on liter-
ature review, the cases of pre-invasive neoplasia should decrease 
by 52 to 67 percent, totaling about 2,471 to 2,911 fewer cases 
of diagnosed and treated cervical cancer in these four countries 
(Nygard et al., 2014).
Another study was done in England on the effects of Cervarix 
and its ASO4 adjuvant. The study was a PATRICIA (Papilloma 
Trial against Cancer in Young Adults) trial which was “phase III, 
double-blind, randomized and using the Hepatitis A vaccine as a 
control.” The study did not exclude anyone based on previous 
or current history of genital warts.  The subjects had a cervical 
sampling done every six months for HPV DNA typing and tested 
for 14 cancerous HPV genotypes (16, 18, 31, 33, 35, 39, 45, 51, 
52, 56, 58, 59, 66, and 68) and another 11 non-cancerous HPV 
genotypes.  In addition, all women were examined every twelve 
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months and had a colposcopy if necessary. In total, 18,644 women 
received at least one dose and were included in this study from 
May 2004 until November 2009. The average monitoring time was 
43.7-47.4 months. The results of this study are quite interesting: 
although the bivalent vaccine only officially covers HPV 16 and 
18, a cross-protection was found that prevents HPV 6, 11, 31 and 
45. The reason for cross-protection may be from the similarities 
in structure and homology within the L1 VLP. However, when 
comparing the response from the L1-specific T helper cell that 
are caused by HPV 6 and 11 in the bivalent and the quadrivalent 
vaccines, the numbers of cells were analogous to each other.  The 
study also proves that there was a greater helper T cells response 
for HPV 31 and 45 in the bivalent vaccine.  The reason for cross 
protection may be from the similarities in structure and homology 
within the L1 VLP. The study concluded that the risks of persistent 
effects decreased with the use of vaccines (Szarewski et al., 2013).
England was the first country to try a national immunization pro-
gram involving Cervarix.  As a result, researchers were able to 
study the records from the general practices and the genitouri-
nary medicine clinics of the general public to observe the trends 
of genital warts. Although it has been proven that Gardasil pre-
vents HPV 6 and 11, the main causes for genital warts, Cervarix 
seems to cross-protect them, which also results in a prevention 
of genital warts. This was proven when the study conducted in 
England noticed the large decrease in genital warts in the immu-
nized female teenage population. The teenage male population 
also had a decreasing rate in reports of genital warts, but it was 
not as significant as the female’s population.  However, there are 
many reasons that may have contributed to the decline; one big 
factor is that the population became more aware of the dangers of 
HPV and genital warts and therefore realized the need to protect 
themselves by abstaining from unsafe intercourse.  More studies 
like this one are needed in order to conclusively state 
that it is the vaccine lowering the cases of genital 
warts in England (Howell-Jones et al., 2013).
Beginning in 2006, the National Immunization Survey-
Teen in the United States conducted a study by calling 
random landlines and cellular phones for its sample. In 
total, 14,133 adolescents (with their guardians’ consent) 
submitted their vaccination history. The results showed 
that the number of adolescents receiving the vaccine for 
each dosage increased each year until the number stag-
nated in 2012. However, in 2012, questionnaires began 
to ask why people opted not to vaccinate their daugh-
ters. The most common answers were that the vaccine 
is not needed, the vaccine is not recommended, there 
are questions about the safety of the vaccine, there is 
a lack of knowledge about the vaccine or disease, and 
that their daughter is not sexually active (Centers for 
Disease Control and Prevention [CDC], 2013).
According to the CDC, about 56 million dosages of Gardasil 
were administered from June 2006 through March 2013, and 
from October 2009 through May 2013, about 611,000 dosages 
of Cervarix were administered in the United States. Analysis of 
vaccine safety by the CDC is limited to Gardasil because it cov-
ers 99% of the vaccinated population. Of the 54 million vaccines 
administered, 21,194 unusual cases were reported in females, and 
92.1% of those cases were considered non-serious. The main bulk 
of these reports were from 2008. Yet, the remaining 7.9% of those 
cases were considered serious, with the highest total from 2009. 
However, these symptoms that occurred after patients received 
the dose are usual symptoms that may occur for most vaccines 
(CDC, 2013).
The ACIP conducted its own trials and safety studies on Cervarix. 
Each Cervarix vaccine administration was observed for any symp-
toms upon injection, like development of a new autoimmune dis-
ease or chronic diseases, injection-site reaction, systemic symp-
toms, and death. Of the 23,713 females studied in the study, 92% 
complained of injection-site swelling, 48% had redness, and 44% 
had swelling. Other common side-effects were myalgia, fatigue and 
headaches.  Only about 5.3% complained of serious results; how-
ever, 5.9% in the control group also complained of serious results 
(CDC, 2010).
Gardasil also performed its own studies on a variable population 
with all different types of ethnicities, ages, gender, and previous his-
tory.  In total, 28,413 people participated in this study, the majority 
of whom were women. In the 16-26 age range for females, the 
efficacy, which was marked by almost one hundred development 
of CIN, VAIN, AIS, VIN, and genital warts, was close to 100 percent 
in all categories, with the lowest rate at 96.9%. The rate in older 
women was not as high as the younger population, where the 
Figure 2: 
The number of serious and non-serious reports of side effects of Gardasil by year from June 
2006-March 2013 (CDC, 2013).
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efficacy rate was approximately 85%.  Men ranging from 16-26 had 
about a 90% efficacy rate. However, the numbers dipped, even at 
some points close to 60% efficacy, in the prior or currently HPV-
infected population. The immunological tests showed good results 
for geometric mean titers and a high percentage of antibodies that 
are anti-HPV 6, 11, 16 and 18 in all subjects. During clinical trials, 
safety was a major area of observation; very few abnormal cases 
and mainly all typical vaccines reactions, like headache, pyrexia, 
diarrhea, nausea, and vomiting were noted. In addition, 258 out of 
29,323 subjects complained of serious reactions like headache, ap-
pendicitis, gastroenteritis, urinary tract infection, and pneumonia. 
Forty people were healthy and died from motor vehicle accidents, 
overdose, cancer, gunshot wounds and pulmonary embolus. Those 
people reflect the all deaths notified in their report so no person 
actually died from the vaccine directly.   
Many more studies like the ones mentioned above have been con-
ducted and analyzed. The common thread among all of them is 
that the vaccine causes an increase titer of antibodies in close to 
100% of the subjects, subjects’ side effects include the regular side 
effects common to all vaccines with the additional of chance of 
syncope, and only less than 10 percent may have had serious impli-
cations afterwards, but nobody ever came close to death because 
of vaccination (Gardasil.com, 2013).
Based on all of these studies, the vaccine seems to enable the 
production of antibodies against HPV in all those vaccinated to 
prevent future cancer. The side effects seem reasonable in com-
parison to all other vaccines. No serious ailments are connected 
to the vaccine directly and the vaccine is deemed to be safe. The 
biggest concern that still remains is how long the vaccine’s im-
munity will last. Since Gardasil has only been distributed to the 
population for eight years and has been studied for a bit over a de-
cade, not much is known as to the long-term effects, both positive 
and negative. Cervarix is even less studied because its worldwide 
distribution began only five years ago. Questions do remain on 
the preference of the two vaccines: Cervarix leads to more than 
double the number of antibodies, whereas Gardasil prevents more 
genotypes and genital warts. As mentioned before, it should be 
the patient’s choice as to which vaccine should be administered to 
him/her. Realistically, the fact that 54 million people had received 
Gardasil while only 600,000 had received Cervarix through 2013 
sheds light on the fact that doctors only have one vaccine in the 
office. This might be because of costs or health insurance cover-
age. Nevertheless, patients should be advised about both vaccines 
and should have the right to ask for whichever one they think is 
properly suited for them. 
Conclusion
In 2006, a new era of science began with the development of a 
cancer vaccine – the HPV vaccine. If an individual has persistent 
HPV infections, he/she has a chance of that HPV virus growing 
into an abnormal growing stage which will eventually become 
cancerous. The newly discovered vaccine has been proven to pre-
vent any further growth of lesions from the HPV virus and to 
prevent these lesions from becoming cancerous. The vaccine also 
gives the vaccinated community anti-HPV antibodies. Gardasil is 
a quadrivalent vaccine and protects against HPV 6,11,16,18 and 
genital warts. Cervarix is a bivalent vaccine that only protects 
against HPV 16 and 18. HPV 16 and 18 are the most significant 
strains as it causes about 70% of all HPV cases. Furthermore, each 
vaccine also cross-protects against other HPV genotypes. Both 
vaccines have an unusual and yet close to 100% efficacy rate and 
the sides-effect for each vaccine are minimal. Very few cases of 
serious side-effects have been reported, which none of them led 
near death or death situation. The vaccine is catered for the 10- 
to 25-year-old age range and best results occur when given to 
individuals who are not yet active or pre-exposed, because the 
vaccine does not cure HPV infections whatsoever.. Although most 
people think HPV is not “catchy,” it is in fact highly contagious and 
is similar to influenza and chicken pox in that it spreads through 
direct contact. HPV can spread from person to person in people 
ten years and older, with the help of the fact not everybody knows 
they have it. Therefore, HPV is a serious matter and the number 
of cases must lessen. If fewer individuals are infected, there will 
be fewer cancers in the world. Similarly, just like the polio vaccine 
fewer to less outbreaks of polio, hopefully one day fewer people 
will contract anal, vaginal, penile and cervical cancer because of 
the influence of the HPV vaccine.  It is important for the public to 
be educated about the harms of HPV, the cancers HPV cause, and 
the benefits and risks of preventive HPV vaccines, Gardasil and 
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